Login / Signup

The molecular mechanism of METTL3 promoting the malignant progression of lung cancer.

Chao MaRui-Jie MaKang HuQi-Ming ZhengYe-Peng WangNan ZhangZhi-Gang Sun
Published in: Cancer cell international (2022)
Lung cancer remains one of the major causes of cancer-related death globally. Recent studies have shown that aberrant m 6 A levels caused by METTL3 are involved in the malignant progression of various tumors, including lung cancer. The m 6 A modification, the most abundant RNA chemical modification, regulates RNA stabilization, splicing, translation, decay, and nuclear export. The methyltransferase complex plays a key role in the occurrence and development of many tumors by installing m 6 A modification. In this complex, METTL3 is the first identified methyltransferase, which is also the major catalytic enzyme. Recent findings have revealed that METTL3 is remarkably associated with different aspects of lung cancer progression, influencing the prognosis of patients. In this review, we will focus on the underlying mechanism of METT3 in lung cancer and predict the future work and potential clinical application of targeting METTL3 for lung cancer therapy.
Keyphrases
  • cancer therapy
  • end stage renal disease
  • ejection fraction
  • risk assessment
  • drug delivery
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • current status
  • human health
  • patient reported